Hematologic Disorders Education Center

Hematological disorders present an enormous set of challenges for clinicians. Healthcare providers are thankful that the treatment alternatives for these disorders are improving at a significant rate and that patient outcomes are improving as well.

The challenge for many clinicians is to keep track of the new pharmacologic approaches to treating hematological disorders. This website has been designed as a resource center for hematologists, oncologists, and other healthcare providers who are involved in the care of these patients.

Manufacturer Withdraws Idelalisib Approval for Follicular B-cell Non-Hodgkin Lymphoma and Small Lymphocytic Leukemia

Manufacturer Withdraws Idelalisib Approval for Follicular B-cell Non-Hodgkin Lymphoma and Small Lymphocytic Leukemia

After an accelerated approval from the FDA in 2014, the makers of idelalisib have decided to withdraw the previously approved indications for relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic leukemia...
FDA Grants Regenerative Medicine Advanced Therapy Designation to CTX110 CAR T-cell Therapy

FDA Grants Regenerative Medicine Advanced Therapy Designation to CTX110 CAR T-cell Therapy

The FDA has granted CTX110 – an allogeneic CAR T-cell therapy that targets CD19+ B-cell malignancies – Regenerative Medicine Advanced Therapy designation...
FDA Approves Abatacept for the Prevention of Acute GVHD

FDA Approves Abatacept for the Prevention of Acute GVHD

The FDA approved abatacept to prevent acute graft versus host disease (aGVHD) for adults and children over the age of two undergoing bone marrow or stem cell transplantation from an unrelated donor...
Tagraxofusp Safe, Effective In Relapsed or Refractory Myelofibrosis

Tagraxofusp Safe, Effective In Relapsed or Refractory Myelofibrosis

Monotherapy with tagraxofusp showed promise in patients with relapsed or refractory myelofibrosis who were previously treated with JAK inhibitors...
FDA Approves Asciminib for Chronic Myeloid Leukemia

FDA Approves Asciminib for Chronic Myeloid Leukemia

The FDA has approved asciminib, a STAMP inhibitor that binds to the ABL myristoyl pocket, for the  treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase...

Loading...

© 2024 /alert® unless otherwise noted. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
Privacy Policy | Terms of Use | Editorial Policy | Advertising Policy